返回 
加入收藏
依拉环素用于ICU中多重耐药菌肺炎患者的疗效和安全性
x
请在关注微信后，向客服人员索取文件
| 篇名： | 依拉环素用于ICU中多重耐药菌肺炎患者的疗效和安全性 |
| TITLE： | Study on the efficacy and safety of eravacycline in ICU patients with multidrug-resistant bacterial pneumonia |
| 摘要： | 目的 评估依拉环素用于重症监护室（ICU）中耐碳青霉烯类鲍曼不动杆菌（CRAB）和/或耐碳青霉烯类肺炎克雷伯菌（CRKP）肺炎患者的临床疗效与安全性。方法收集2023年7月至2024年11月入住中国医学科学院北京协和医院ICU并接受依拉环素治疗的CRAB和/或CRKP肺炎患者资料。记录患者治疗后28d全因死亡率、临床失败率、存活患者28d无ICU时间、存活患者28d无机械通气时间、微生物学转阴情况及不良反应发生情况。结果共纳入37例患者。37例患者中，临床失败患者11例（29.73%），治疗后患者28d全因死亡7例（18.92%）；存活患者28d无ICU时间为（14.60±10.61）d、存活患者28d无机械通气时间为（24.55±4.29）d；12例（32.43%）患者微生物学转阴，平均转阴时间为（10.58±12.05）d。5例患者发生不良反应，总发生率为13.51%，包括2例肝酶升高、2例凝血功能障碍、1例药物超敏反应综合征。结论依拉环素可有效控制ICU中CRAB和/或CRKP肺炎患者的全身细菌感染及炎症反应，但合并基础肝病、联合使用多种抗菌药物的患者需警惕肝酶升高、凝血功能异常以及罕见的药物超敏反应综合征。 |
| ABSTRACT： | OBJECTIVE To evaluate the clinical efficacy and safety of eravacycline in intensive care unit （ICU） patients with carbapenem-resistant Acinetobacter baumannii （CRAB） and/or carbapenem-resistant Klebsiella pneumoniae （CRKP） pneumonia.METHODS Clinical data of patients with CRAB and/or CRKP pneumonia who were admitted to the ICU of Peking Union Medical College Hospital， Chinese Academy of Medical Sciences， and received eravacycline treatment from July 2023 to November 2024 were collected. The 28-day all-cause mortality rate， clinical failure rate， 28-day ICU-free days among surviving patients， 28-day mechanical ventilation-free days among surviving patients， microbiological clearance， and adverse reactions were recorded.RESULTS A total of 37 patients were included. Among the 37 patients， 11 （29.73%） experienced clinical failure， and the 28-day all-cause mortality rate was 18.92% （7/37）. The 28-day ICU-free days among surviving patients were （14.60±10.61） days， and the 28-day mechanical ventilation-free days among surviving patients were （24.55±4.29） days. Microbiological clearance was achieved in 12 patients （32.43%）， and the mean time to conversion was （10.58±12.05） days. Adverse reactions occurred in 5 patients （13.51%）， including 2 cases of elevated liver enzymes， 2 cases of coagulopathy， and 1 case of drug hypersensitivity syndrome.CONCLUSIONS Eravacycline can effectively control systemic bacterial infection and inflammatory response in ICU patients with pneumonia caused by CRAB and/or CRKP. However， patients with underlying liver disease or receiving multiple antibacterial agents should be alert to elevated liver enzymes， coagulation abnormalities， and the rare drug hypersensitivity syndrome. |
| 期刊： | 2026年第37卷第19期 |
| 作者： | 梁春苏；李丽美；许婷婷；左玮 |
| AUTHORS： | LIANG Chunsu，LI Limei，XU Tingting，ZUO Wei |
| 关键字： | 依拉环素;耐碳青霉烯类鲍曼不动杆菌;耐碳青霉烯类肺炎克雷伯菌;肺炎;重症监护病房 |
| KEYWORDS： | eravacycline;carbapenem-resistant Acinetobacter baumannii ;carbapenem-resistant Klebsiella pneumoniae ;Pneumonia;Intensive care unit |
| 阅读数： | 2 次 |
| 本月下载数： | 0 次 |
* 注：未经本站明确许可，任何网站不得非法盗链资源下载连接及抄袭本站原创内容资源!在此感谢您的支持与合作！
